Lannett Co. Inc. (LCI)

6.79
1.60 19.00
NYSE : Health Technology
Prev Close 8.42
Open 8.22
Day Low/High 6.77 / 8.35
52 Wk Low/High 3.33 / 14.20
Volume 5.33M
Avg Volume 1.04M
Exchange NYSE
Shares Outstanding 39.32M
Market Cap 235.16M
EPS 0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Lannett Enters Into Distribution Agreement For Levothyroxine

Lannett Enters Into Distribution Agreement For Levothyroxine

PHILADELPHIA, July 8, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a future exclusive supply and distribution agreement for the approved Levothyroxine Sodium Tablets USP of Cediprof, Inc.

FDA Clears Path For The Continuing Review Of Lannett Company's New Drug Application

FDA Clears Path For The Continuing Review Of Lannett Company's New Drug Application

PHILADELPHIA, July 3, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today commented on the U.

Lannett Breaks Above 200-Day Moving Average - Bullish For LCI

Lannett Breaks Above 200-Day Moving Average - Bullish For LCI

In trading on Friday, shares of Lannett Co., Inc. crossed above their 200 day moving average of $6.35, changing hands as high as $6.40 per share.

Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch

Lannett Enters Into Distribution Agreement For Dantrolene Capsules, Commences Product Launch

PHILADELPHIA, June 28, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.

Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules

Lannett Launches Aspirin And Extended-Release Dipyridamole Capsules

PHILADELPHIA, June 18, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug,...

Lannett To Participate At Two Investor Conferences In June

Lannett To Participate At Two Investor Conferences In June

PHILADELPHIA, June 12, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced its participation at two upcoming investor conferences.

Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus®

Lannett Announces Initiation Of Human Clinical Trial Of Biosimilar Insulin Glargine Versus Us Lantus®

PHILADELPHIA, June 5, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the commencement of a human clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the...

Lannett Commences Marketing Generic Concerta®

Lannett Commences Marketing Generic Concerta®

PHILADELPHIA, May 29, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths, an AB-rated...

Lannett Is Now Oversold (LCI)

Lannett Is Now Oversold (LCI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Lannett Announces CFO Retirement

Lannett Announces CFO Retirement

PHILADELPHIA, May 24, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company's chief financial officer (CFO), Martin Galvan, 67, will retire on August 30, 2019, following the planned submission of the company's Form 10-K...

(LCI) Alert: Johnson Fistel, LLP Announces Investigation Of Lannett Company, Inc.; Long Term Investors Encouraged To Contact Firm

(LCI) Alert: Johnson Fistel, LLP Announces Investigation Of Lannett Company, Inc.; Long Term Investors Encouraged To Contact Firm

SAN DIEGO, May 23, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential violations of federal and state laws by Lannett Company, Inc.

Lannett Appoints Melissa V. Rewolinski, PhD, To Board Of Directors

Lannett Appoints Melissa V. Rewolinski, PhD, To Board Of Directors

PHILADELPHIA, May 23, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Melissa V.

Lannett Purchases Additional $30.5 Million Of Term A Loans

Lannett Purchases Additional $30.5 Million Of Term A Loans

PHILADELPHIA, May 21, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $30.

Lannett Begins Marketing Generic Adderall®

Lannett Begins Marketing Generic Adderall®

PHILADELPHIA, May 16, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it has begun marketing a generic version of Adderall ®, an immediate-release (IR) mixed salt of a single entity Amphetamine tablet product (Dextroamphetamine...

First Week Of LCI June 21st Options Trading

First Week Of LCI June 21st Options Trading

Investors in Lannett Co., Inc. saw new options begin trading this week, for the June 21st expiration.

LANNETT INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lannett Company, Inc. To Contact The Firm

LANNETT INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lannett Company, Inc. To Contact The Firm

NEW YORK, May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Lannett Company, Inc.

SHAREHOLDER ALERT: Investigation Of Lannett Announced By Holzer & Holzer, LLC

SHAREHOLDER ALERT: Investigation Of Lannett Announced By Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Lannett Company, Inc.

LCI Crosses Above Average Analyst Target

LCI Crosses Above Average Analyst Target

In recent trading, shares of Lannett Co., Inc. have crossed above the average analyst 12-month target price of $9.00, changing hands for $9.08/share.

Lannett Announces Fiscal 2019 Third-Quarter Financial Results; Raises Guidance For Fiscal 2019

Lannett Announces Fiscal 2019 Third-Quarter Financial Results; Raises Guidance For Fiscal 2019

- Net Sales, Excluding Levothyroxine, Continues Sequential Quarterly Growth

Notable Monday Option Activity: LCI, AXGN, GIII

Notable Monday Option Activity: LCI, AXGN, GIII

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lannett Co., Inc. , where a total volume of 11,446 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares).

Lannett To Launch Generic Concerta®, AB-rated Methylphenidate Hydrochloride ER Tablets

Lannett To Launch Generic Concerta®, AB-rated Methylphenidate Hydrochloride ER Tablets

PHILADELPHIA, April 30, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it expects to launch later this quarter Methylphenidate Hydrochloride Extended Release (ER) tablets USP (CII) in 18 mg, 27 mg, 36 mg and 54 mg strengths,...

Lannett To Report Fiscal 2019 Third-Quarter Financial Results, Host Conference Call On Monday, May 6

Lannett To Report Fiscal 2019 Third-Quarter Financial Results, Host Conference Call On Monday, May 6

PHILADELPHIA, April 29, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 third quarter on Monday, May 6, 2019, after the market closes.

Bullish Two Hundred Day Moving Average Cross - LCI

Bullish Two Hundred Day Moving Average Cross - LCI

In trading on Friday, shares of Lannett Co., Inc. crossed above their 200 day moving average of $7.30, changing hands as high as $7.36 per share.

LCI Crosses Above Key Moving Average Level

LCI Crosses Above Key Moving Average Level

In trading on Friday, shares of Lannett Co., Inc. crossed above their 200 day moving average of $7.94, changing hands as high as $7.95 per share.

Lannett Receives FDA Approval For Aspirin And Extended-Release Dipyridamole Capsules, 25 Mg/200 Mg

Lannett Receives FDA Approval For Aspirin And Extended-Release Dipyridamole Capsules, 25 Mg/200 Mg

PHILADELPHIA, March 27, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it received approval from the U.

Lannett Purchases $24 Million Of Term Loans In Open Market Transactions

Lannett Purchases $24 Million Of Term Loans In Open Market Transactions

PHILADELPHIA, March 21, 2019 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it completed the purchase of approximately $24.

LCI: Insiders Vs. Shorts

LCI: Insiders Vs. Shorts

The most recent short interest data was recently released for the 02/28/2019 settlement date, and Lannett Co., Inc. is one of the most shorted stocks of the Russell 3000, based on 13.37 "days to cover" versus the median component at 4.57.

TheStreet Quant Rating: D (Sell)